Tech Company Financing Transactions
Magenta Therapeutics Funding Round
On 5/3/2017, Magenta Therapeutics raised $50 million in Series B funding from GV, Access Industries and Atlas Accelerator.
Transaction Overview
Company Name
Announced On
5/3/2017
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
The financing announced today is intended to fuel development of innovative product candidates across multiple aspects of transplantation medicine, including more precise preparation of patients, stem cell harvesting and stem cell expansion.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Technology Sq. 5th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jason Gardner
Chief Medical Officer
John Davis
Chief Operating Officer
Jason Ryan
Vice President
Manisha Pai
VP - Bus. Development
Christina Isacson
VP - General Counsel
Zoran Zdraveski
VP - Human Resources
Kristen Stants
Browse more venture capital transactions:
Prev: 5/3/2017: Cocrystal Discovery venture capital transaction
Next: 5/3/2017: Iconixx venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records on this site come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs